Objectives: To implement the widespread treatment of hepatitis C virus (HCV), validated self-report measures to assess medication adherence are needed for monitoring patients who are prescribed HCV directacting antivirals (DAAs). The Visual Analog Scale (VAS) is an efficient and well-validated tool for measuring adherence to antiretrovirals in human immunodeficiency virus populations. This study compared VAS scores with pill counts and serum levels of HCV RNA in a sample of HCV-infected veterans prescribed DAAs.
C
hronic infection with the hepatitis C virus (HCV) is the leading cause of liver disease and liver transplantation in the United States. 1 Successful treatment of HCV reduces the risk of developing cirrhosis and primary liver cancer. Until recently, HCV treatment consisted of combination therapy with peginterferon and ribavirin for 24 to 48 weeks, a poorly tolerated regimen that achieved complete remission of HCV viremia, also known as sustained virologic response (SVR), in less than half of all treatment cases. 1 Increased understanding of the HCV life cycle has allowed for development of newer medications which, unlike interferon and ribavirin, interfere directly with HCV replication. These newer therapies, also known as direct-acting antiviral (DAA) medications, have reduced the length of HCV treatment, improved tolerance of HCV therapy, and dramatically increased rates of SVR.
Despite the high success rate of DAAs, some patients are excluded from treatment consideration because of concerns for nonadherence. In a qualitative study primary care and hepatology providers were reluctant to assess patients with ongoing substance use disorder, mental health conditions, and lack of stable housing for HCV DAA treatment because of perceived risks for nonadherence. 2 Because individuals with these characteristics also have a higher prevalence of HCV infection than the general population, 3 patient adherence is a barrier to the expansion of DAA treatment.
The US Viral Hepatitis Action Plan for 2017-2020 calls for widespread implementation of DAA treatment to reduce the number of deaths from hepatitis C by one-fourth. 4 One of the designated approaches to achieve the goals in this ambitious plan is to "develop and test approaches to support viral hepatitis treatment adherence by patients." 4 The National Institutes of Health Consensus Conference Statement on Management of Hepatitis C also specified "patient adherence" as "critical" to the successful management of HCV. 5 Unfortunately, measurement of medication adherence is not widely implemented in HCV care 6 and evidence-based methods of measuring adherence to HCV medications are lacking. To date, the majority of published studies measuring adherence to HCV antivirals have relied on pharmacy refill data and pill counts, 7, 8 which measure two different aspects of medication-taking behavior. Pharmacy refill data reflect medication persistence, or completing the recommended length of treatment. 9 Because some early treatment discontinuations could be medically necessary, treatment persistence may not be entirely patient driven. 10 In contrast, pill counts measure medication adherence, that is, patients' daily conformity to the recommended medical regimen. 9 Although medication persistence and medication adherence both provide important information regarding medication-taking behaviors, in this article we focus on medication adherence.
Medication adherence is a behavioral outcome, and as such can be difficult to measure accurately. 11 Although clinical studies often rely on pill counts to measure medication adherence, this practice can be logistically challenging in real-world settings. Patients often do not bring their medication bottles, often are uncertain of the start date of medications, and may dispose of the medication without ingesting it. Clinicians may not have the time or support personnel to perform pill counts. Pill counts also may negatively affect the patient-provider relationship because it can be seen as a violation of trust between the two parties.
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The Visual Analog Scale (VAS) is a single-item, self-report measure of medication adherence that has been validated in patients receiving human immunodeficiency virus (HIV) antiretroviral medications in a variety of clinical settings. [12] [13] [14] Among people living with HIV, the VAS has demonstrated concordance with several objective measures of adherence, including Medical Event Monitoring System data, pill counts, and suppression of HIV viral load. 12, 15, 16 Compared with pill counts, the VAS is less time intensive, can be used in a group setting, and can be administered by a nonprofessional (eg, a trained clerk). Moreover, the VAS eliminates the need to obtain additional information (eg, prescription fill date, number of pills dispensed) and minimizes potential mathematical errors because it relies on a single data point. The purpose of this study was to compare VAS results with pill counts and HCV viral load in a sample of HCVinfected veterans prescribed DAAs.
Methods

Ethics
This study received ethics approval from the institutional review board of the G.V. (Sonny) Montgomery Veterans Affairs (VA) Medical Center and written informed consent was obtained on all of the participants.
Study Population
The G.V. (Sonny) Montgomery VA Medical Center is an urban, academically affiliated center in Jackson, Mississippi. In fiscal year 2014, the HCV clinics in the medical center provided follow-up to approximately 1000 veterans with chronic HCV infection, one-fourth of whom had a diagnosis of cirrhosis. 17 During the enrollment period of this study, DAA uptake was relatively low, with 32 patients initiating HCV treatment at this facility in fiscal year 2014. 17 
Study Procedures
Veterans initiating DAAs for HCV treatment were eligible for study participation provided they had no contraindications to the planned course of DAA therapy; were not co-infected with HIV, hepatitis B, or both; and did not have a history of decompensated liver disease. A convenience sample of patients was recruited during routine HCV clinic appointments. After providing written informed consent, veterans completed a survey of demographic information and current medication use. HCV treatment was prescribed in accordance with standard of care; use of peginterferon and/or ribavirin was permitted. All of the medications were provided by the VA pharmacy. Follow-up visits were scheduled every 28 days for a total of 12 weeks, and patients received a 28-day supply of each medication, which was dispensed onsite. Patients received $25 per study visit.
Measures of Adherence
Adherence to DAAs was assessed at follow-up visits using VAS scores and pill counts. The VAS survey used in the study was a 100-mm horizontal line anchored by word descriptions at either end (Fig) . The stem or introductory portion, which was read by a trained interviewer, encouraged veterans to be accurate in their self-reported adherence during the previous 4 weeks. The patient verbally provided the name of his or her medication and the prescribed dosing intervals. The interviewer then demonstrated the equivalence of 0%, 50%, and 100% adherence on the scale. The patient marked his or her level of adherence (any value in the range of 0%-100%) to the medication during the previous 4-week interval. The VAS was scored by measuring the distance in millimeters between zero and the patient's mark, which was recorded as percentage of adherence. The same interviewer performed the VAS score with each patient at each follow-up visit.
Pill counts were selected to compare with the VAS, as they have been used in previous investigations of adherence to HCV DAAs. 7, 18 The number of each dispensed medication was recorded at weeks 0, 4, and 8. Patients returned their packages and bottles at visits 4, 8, and 12. At each visit, the remaining pills or capsules were recorded by trained study personnel. Adherence was calculated as follows:
In accordance with standard of care, boceprevir was prescribed at week 4 of treatment; therefore, adherence to boceprevir was assessed at weeks 8 and 12. Adherence to all other DAAs (eg, sofosbuvir, simeprevir) was assessed at weeks 4, 8, and 12. Serum levels of HCV RNA were measured at baseline, 4 weeks after DAA initiation (week 8 for boceprevir, week 4 other DAAs), and week 12 of HCV treatment (Cobas Ampliprep/Taqman, lower limit of quantification 43 IU/mL, Roche Diagnostics, Indianapolis, IN). If patients were receiving more than one DAA (eg, sofobuvir and simeprevir), the adherence measured via pill count and VAS score were combined and the mean adherence was reported for each time point (weeks 4, 8, and 12).
Data Analysis
Data were analyzed using SPSS version 21 (IBM SPSS Statistics, Armonk, NY). Pill counts and VAS were compared using the Wilcoxon signed rank test; significance level was adjusted to 0.017 to account for familywise error. Correlation coefficients were calculated using the Pearson correlation coefficient (r). 19 
Results
Description of Study Sample
Between May 1, 2013 and December 31, 2014, 30 veterans were enrolled (Table 1) . Most patients were men (n = 26) and white (n = 17). The major infecting genotype was 1a (n = 13), followed by 1b (n = 9), 1 undifferentiated (n = 5), and 2b (n = 3). Current substance use (past 6 months) was uncommon, with only 6 (20%) participants reporting alcohol use and 3 (10%) participants reporting cannabis use. No patients reported current use of cocaine, amphetamines, or other illicit drugs. Nine patients (30%) reported at least one previous psychiatric 
Study Endpoints
A high rate of adherence to DAAs (boceprevir, sofosbuvir, simeprevir) was observed in our cohort. In patients receiving two DAAs (n = 5), there was no difference in adherence at each time point (P = 1.0). Mean adherence via pill count at weeks 4, 8, and 12 (96.2%, 95.2%, and 98.2%, respectively) was nearly identical to the mean VAS scores at each time point (96.2%, 96.0%, and 98.2, respectively), with no significant differences between VAS scores and pill counts ( Table 2 ). The VAS score demonstrated a strong inverse correlation with HCV viral load 4 weeks after DAA initiation (r −0.98) and at 12 weeks of treatment (r −0.97; Table 3 ).
Discussion
Studies of HCV DAAs suggest that a high level of adherence is critical to attain maximal SVR rates and reduce the development of drug resistance. 20, 21 Data with the first-generation DAA telaprevir in combination with peginterferon and ribavirin suggested that medication adherence of <95% as measured by pill count could result in treatment failure. 18 In clinical trials of ledipasvir/sofosbuvir, patients who had >80% adherence by pill count had substantially higher rates of SVR than those who did not (97.1% vs 82.5%, respectively, P < 0.0001). 22 As such, brief and validated methods of monitoring medication adherence that can be deployed in a variety of clinical settings are essential for the management of HCV. One such method that may meet these requirements is the VAS, which is a single-item, self-report measure that has been validated in ethnically and culturally diverse ranges of HIV populations receiving antiretrovirals. To be useful to clinical practice, a self-report measure must not only be culturally adaptable but also should demonstrate strong correlations with objective measures of adherence and biological outcomes. In our convenience sample of HCV-infected veterans receiving DAAs, the VAS revealed statistically similar results to pill counts and demonstrated a strong inverse correlation with serum levels of HCV RNA. Our data therefore suggest that the VAS may provide a practical and reliable means to identify patients with barriers to adherence in real-world HCV clinics. Although widely studied in HIV populations, we could find only one previous study that examined the VAS as a clinical tool to measure adherence among HCVinfected patients. A cross-sectional survey conducted in an HIV clinic used the VAS to assess adherence to peginterferon and ribavirin among 72 HIV/HCV co-infected patients. 23 The majority of the sample had completed HCV treatment before the survey was conducted and VAS scores were not compared with an objective measurement of adherence. 23 The authors reported that VAS scores that predicted 100% adherence were significantly associated with higher rates of treatment completion and SVR. 23 To our knowledge, our study is the first that used the VAS as an adherence measurement tool prospectively during HCV DAA treatment.
We also observed that VAS scores inversely correlated with a decline in serum levels of HCV RNA. The relation of adherence to decline in serum levels of HCV viral load was previously identified in studies of HCV treatment with peginterferon and ribavirin. A retrospective cohort study of 188 veterans found that adherence of ≥85% was associated with a significant decline in HCV RNA at week 12 of treatment. 24 A cohort study of 5706 veterans confirmed that increased levels of adherence to peginterferon and ribavirin were associated with a ≥2 log decline in HCV RNA at week 12 of treatment. 25 In the Viral Resistance to Antiviral Therapy of Chronic Hepatitis C clinical trial, self-reported adherence assessed using a computer-based questionnaire was associated with overreporting of peginterferon and ribavirin adherence as compared with electronic drug monitoring. 26 In our study, adherence measured by the VAS, a self-report tool, was equivocal to pill counts. We attribute our results to the methodology applied to our use of the VAS in the study. In a metaanalysis of HIV adherence studies, protocols that "normalized nonadherence" and administered the VAS as part of an interview demonstrated stronger relations between VAS scores and objectives measures of adherence.
14 Our study used a VAS stem designed to encourage accurate reporting of doses taken. We also used a trained interviewer to administer the VAS, a technique surmised to improve patient comprehension.
14 Because the VAS requires patients to think in percentages, a trained interviewer may be particularly important to the success of the VAS among patients with lower health literacy. We suggest that future studies of the VAS in HCV treatment clinics incorporate language to discourage overreporting and administer the VAS through a trained interviewer.
The limitations to our study include the small sample size and single-center enrollment. As a survey of veterans at one medical center, our results may not be generalizable to other HCV-infected populations. As a self-report measure, the VAS is subject to recall bias, overreporting, and social desirability. The medications used in this study are no longer standard of care for HCV treatment; however, medication adherence remains an important component of HCV care to expand treatment to all HCV-infected individuals. The VAS is well suited to this treatment expansion because it has been validated in a wide variety of clinical settings and medication regimens, including oncedaily HIV antiretrovirals. 27 
Conclusions
We used the VAS to assess adherence to DAAs in a real-world HCV treatment clinic. We observed a strong relation of VAS to pill count and declines in HCV viral load in our sample of HCV-infected veterans receiving first-generation DAAs. The benefits of using the VAS over pill counts to measure adherence include ease of administration, lack of reliance of ancillary data, and minimal burden on clinic staff. If future studies confirm our results, then we believe the VAS may provide an efficient tool for assessing adherence to HCV DAAs in clinical practice.
